



Clear dosage selection criteria

60 mg
 once daily

**RECOMMENDED DOSE FOR
 STROKE PREVENTION IN AF***



30 mg
 once daily

**FOR PATIENTS MEETING ONE OR
 MORE OF THE FOLLOWING CRITERIA:**



**Covered by
 provincial formulary!
 (Exception Drug
 Status)**

Check your provincial listing for
 coverage criteria.




**Can now be prescribed for patients with severe renal
 impairment (CrCL 15–29 mL/min)**



**Moderate (CrCL 30–50 mL/min)
 or severe (CrCL 15–29 mL/min)
 renal impairment†**

(not recommended in patients with end
 stage renal disease [CrCL < 15 mL/min]
 or on dialysis)



**Low body
 weight**

≤ 60 kg
 (132 lb.)



**Concomitant use
 of P-gp inhibitors**

such as cyclosporine,
 dronedarone, erythromycin,
 ketoconazole, and
 quinidine. Amiodarone and
 verapamil are exceptions.






or

or

CrCL: creatinine clearance; P-gp: P-glycoprotein
 *Consult the Product Monograph for complete dosing
 and administration information.
 †Estimated CrCL should be determined in all patients
 prior to start of LIXIANA[®] treatment.

CrCL should be monitored at the beginning of the treatment in all patients and afterwards when
 clinically indicated. Plasma concentration of LIXIANA[®] is increased with the degree of renal impairment.
 LIXIANA[®] (edoxaban) is indicated for prevention of stroke and systemic embolic events in patients with
 atrial fibrillation (AF), in whom anticoagulation is appropriate.

Comparison of recommended dosing of NOACs for use in the prevention of stroke and systemic embolic events in patients with AF

	Recommended dose	Frequency	Oral administration
LIXIANA[®] (edoxaban) ^{*,1}	60 mg	1x Once daily	 With or without food
XARELTO[®] (rivaroxaban) ^{*,6}	20 mg	1x Once daily	 With food (15 and 20 mg)
ELIQUIS[®] (apixaban) ^{*,7}	5 mg	2x Twice daily (10 mg total daily dose)	 With or without food
PRADAXA[®] (dabigatran etexilate) ^{*,8}	150 mg	2x Twice daily (300 mg total daily dose)	  With or without food PRADAXA [®] should be taken with a full glass of water. PRADAXA [®] should be taken with meals in patients with dyspepsia.†

Adapted from the LIXIANA[®], XARELTO[®], ELIQUIS[®], and PRADAXA[®] Product Monographs. Trademarks are the property of their respective owners.

*Data from separate Product Monographs; comparative clinical significance unknown.

†Based on clinical judgment, treatment with a proton pump inhibitor may be considered in patients still experiencing dyspepsia despite taking PRADAXA[®] with or within 30 minutes after a meal.

Refer to the respective Product Monographs for complete dosing and administration information, including dose reductions, special populations, and drug interactions.

LIXIANA[®] should be taken regularly, as prescribed, to ensure optimal effectiveness. All temporary discontinuations should be avoided, unless medically indicated.

If a dose is missed, the dose must be taken as soon as possible on the same day. The dose should not be doubled to make up for the missed dose. Patients should return to their normal schedule the next day.

NOAC: non-vitamin K antagonist oral anticoagulant

Convenient once-daily dosing



DOSING FREQUENCY:
One-pill, once-daily
dosing^{*,1}




**ORAL
ADMINISTRATION:**
Taken with or
without food^{*,1}

A manageable transition process

Recommendations for switching to LIXIANA®

Continued anticoagulant therapy is important for stroke prevention in patients with AF. There may be situations that warrant a change in anticoagulation therapy.



Refer to the Product Monograph for complete dosing and administration information, including complete recommendations for switching to and from LIXIANA®, dose reductions, special populations, and drug interactions.

Consult the Product Monograph at www.servier.ca/sites/default/files/webform/products/product-monograph-Lixiana-EN.pdf for important information relating to contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling us at 1-800-363-6093 or by visiting www.servier.ca.

Please visit www.servier.ca/references/Lixiana_EN.pdf to access the reference list.

VKA: vitamin K antagonist; INR: international normalized ratio
^{*}Consult the Product Monograph for complete dosing and administration information.

once-daily
Lixiana[®]
edoxaban tosylate
monohydrate tablets




**COVERED BY
PROVINCIAL
FORMULARY!**

**Exception
Drug Status**

Check your provincial listing
for coverage criteria.



Convenient
once-daily
dosing*



Taken with
or without
food



Clear dosage
selection
criteria



*Consult the Product Monograph for complete dosing and administration information.

Servier Canada Inc. 235, boulevard Armand-Frappier, Laval, QC H7V 4A7
www.servier.ca | 1-888-902-9700

® Registered trademark of Daiichi Sankyo Co., Ltd. Used under licence.
© 2022 Servier Canada Inc. All rights reserved.

